Biosensors International Group, Ltd
William Adams has a robust background in Quality Assurance and Validation within the biomedical and medical device industries, holding key positions across multiple organizations. As Director of Quality Assurance at Biosensors International USA, William oversaw all quality aspects of Pilot Plant operations and managed Quality Engineering and Documentation Control from January 2005 to January 2008. Prior to that role, William served as Director of Quality Assurance and Validation Manager at Grifols Biologicals, successfully closing outstanding compliance issues. William also held Validation Manager roles at Alpha Therapeutics Corporation and Alpha Therapeutic Inc., where responsibilities included qualification of raw materials and supplier management. Earlier in the career, as Director of Quality Assurance at Alliance Medical Technologies Inc., William facilitated the PMA approval for the Monostrut Heart Valve and obtained various certifications. William holds a Bachelor of Science in Mechanical Engineering from California Polytechnic State University-San Luis Obispo and a certification in Biomedical Engineering from the University of California, Irvine.
This person is not in any teams
This person is not in any offices
Biosensors International Group, Ltd
Biosensors International develops, manufactures and markets pioneering interventional cardiology devices. The BioMatrix™ DES family features Biolimus A9™ (BA9™), a highly lipophilic anti-restenotic drug designed for cardiovascular stent technologies patented by Biosensors, combined in a unique abluminal biodegradable polymer coating. BioMatrix Alpha™, the latest addition to the family, is a CoCr stent featuring an innovative hybrid design, thin struts and an advanced delivery system. BioFreedom™ demonstrated superior safety and efficacy vs BMS in High Bleeding Risk patients in the landmark LEADERS FREE trial and features a selectively micro-structured abluminal surface allowing polymer & carrier free delivery of BA9™. Recently Biosensors’ parent company made a significant investment into the rapidly growing field of structural heart disease intervention through the acquisition of the company New Valve Technology (NVT), the developers of the flagship product Allegra™ transfemoral TAVI system. Together, Biosensors and NVT will leverage our their respective innovative expertise in Cardiovascular and Structural Heart technologies. Our aim is to improve patients’ lives through pioneering medical technology that pushes the boundaries of innovation. Through our high quality medical devices we impact the lives we touch and we are committed to continued investment in the development of pioneering medical technology, robust clinical data and engineering new medical devices that will further benefit your patients.